登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
RAS 10, monoclonal
Species reactivity:
human
Application:
immunocytochemistry
western blot
western blot
Technique(s):
immunocytochemistry: suitable
western blot: suitable
western blot: suitable
Citations:
17
Uniprot accession no.:
产品名称
抗-Pan-Ras抗体,克隆RAS 10, clone RAS 10, from mouse
biological source
mouse
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
RAS 10, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
western blot: suitable
isotype
IgG2aκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... KRAS(3845)
Analysis Note
对照
MCF7细胞裂解物
MCF7细胞裂解物
通过蛋白质印迹法在MCF7细胞裂解物中进行评估。
蛋白质印迹分析:1 µg/mL该抗体在10 µg MCF7细胞裂解物中检测到Pan-Ras。
蛋白质印迹分析:1 µg/mL该抗体在10 µg MCF7细胞裂解物中检测到Pan-Ras。
Application
使用经验证可用于蛋白质印迹法、ICC的抗Pan-Ras抗体(克隆RAS 10)检测Pan-Ras。
研究子类别
生长因子 & 受体
生长因子 & 受体
研究类别
信号传导
信号传导
蛋白质印迹分析:该抗体的代表性批次在SW-480细胞裂解物中检测到Pan-Ras。
免疫细胞化学分析:该抗体以1:500稀释度在A431细胞中检测到Pan-Ras。
免疫沉淀分析:一个来自独立实验室代表性批次在IP中免疫沉淀Pan-Ras(Hamer,P.J.,et al.(1990).Hybridoma.9(6):573-587.)。
免疫细胞化学分析:该抗体以1:500稀释度在A431细胞中检测到Pan-Ras。
免疫沉淀分析:一个来自独立实验室代表性批次在IP中免疫沉淀Pan-Ras(Hamer,P.J.,et al.(1990).Hybridoma.9(6):573-587.)。
Disclaimer
除非我们的目录或产品随附的其他公司文件中另有说明,否则我们的产品预期仅用于研究用途,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。
General description
人ras基因家族由三个已鉴别的成员H-、K-和N-ras组成,它们编码188-189个氨基酸和21,000(p21)道尔顿的蛋白质。人H-和K-ras是v-H-和v-K-ras的同系物,v-H-和v-K-ras是最初从大鼠肉瘤病毒的Harvey和Kirsten株中分离的序列。正常人细胞ras基因被称为原癌基因,并且具有通过密码子12、13和61中发生的突变而激活为癌基因的潜力。已经从人肿瘤和培养的肿瘤细胞中鉴定和分离了这种突变的、活化的和转化的ras基因。尽管已知ras原癌基因蛋白在正常人体组织中的表达模式,但有关激活的ras癌基因编码的p21s及其与人类疾病诊断和预后的相关性的类似信息仍在出现。
观测分子量〜21 kDa
Immunogen
对应于人Pan-Ras的重组蛋白。
Other Notes
浓度:关于批次特定浓度请参见检验报告。
Physical form
形式:纯化
纯化的小鼠单克隆IgG2aκ,溶于含0.1 M Tris-甘氨酸(pH 7.4)、150 mM NaCl和0.05%叠氮化钠的缓冲液中。
纯化蛋白G
Preparation Note
自接收之日起,在2-8°C下可稳定保存1年。
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Won-Ji Ryu et al.
Experimental & molecular medicine, 52(5), 832-842 (2020-05-28)
Triple-negative breast cancer (TNBC) is a severe and heterogeneous disease that lacks an approved targeted therapy and has a poor clinical outcome to chemotherapy. Although the RAS-ERK signaling axis is rarely mutated in TNBC, ~50% of TNBCs show an increased
F Roßner et al.
Oncogenesis, 5, e187-e187 (2016-01-19)
The transcription factor YBX1 can act as a mediator of signals transmitted via the EGFR-RAS-MAPK axis. YBX1 expression has been associated with tumor progression and prognosis in multiple types of cancer. Immunohistochemical studies have revealed dependency between YBX1 expression and
Sang-Kyu Lee et al.
EMBO reports, 19(12) (2018-11-11)
RAS proteins play critical roles in various cellular processes, including growth and transformation. RAS proteins are subjected to protein stability regulation via the Wnt/β-catenin pathway, and glycogen synthase kinase 3 beta (GSK3β) is a key player for the phosphorylation-dependent RAS
Won-Ji Ryu et al.
Cancers, 11(4) (2019-04-11)
: Treatment of advanced gastric cancer patients with current standard chemotherapeutic agents frequently results in resistance, leading to poor overall survival. However, there has been no success in developing strategies to overcome it. We showed the expression levels of both
Alisa Damnernsawad et al.
Haematologica, 107(1), 77-85 (2020-12-31)
Drug resistance impedes the long-term effect of targeted therapies in acute myeloid leukemia (AML), necessitating the identification of mechanisms underlying resistance. Approximately 25% of AML patients carry FLT3 mutations and develop post-treatment insensitivity to FLT3 inhibitors, including sorafenib. Using a
相关内容
New Products: Antibodies, Assays, Small Molecules, Inhibitors, and Proteins
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持